Innophos Holdings, Inc. (NASDAQ:IPHS) has been given an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.

Zacks has also assigned Innophos an industry rank of 48 out of 265 based on the ratings given to related companies.

A number of research firms have commented on IPHS. Zacks Investment Research downgraded shares of Innophos from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 4th. KeyCorp reiterated a “hold” rating on shares of Innophos in a research note on Wednesday, November 1st. Finally, BidaskClub upgraded shares of Innophos from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd.

Innophos (NASDAQ:IPHS) opened at $46.43 on Monday. Innophos has a 52 week low of $41.66 and a 52 week high of $58.22. The company has a current ratio of 2.86, a quick ratio of 1.49 and a debt-to-equity ratio of 0.83. The company has a market cap of $906.73, a price-to-earnings ratio of 21.40 and a beta of 0.85.

Innophos (NASDAQ:IPHS) last posted its quarterly earnings data on Tuesday, October 31st. The specialty chemicals company reported $0.78 EPS for the quarter, beating the Zacks’ consensus estimate of $0.72 by $0.06. Innophos had a net margin of 6.19% and a return on equity of 13.90%. The firm had revenue of $184.00 million for the quarter, compared to the consensus estimate of $179.33 million. During the same period in the prior year, the firm posted $0.69 EPS. The firm’s revenue was down 1.1% compared to the same quarter last year. equities research analysts predict that Innophos will post 2.5 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its holdings in shares of Innophos by 0.9% during the second quarter. The Manufacturers Life Insurance Company now owns 14,962 shares of the specialty chemicals company’s stock worth $656,000 after purchasing an additional 130 shares during the period. Public Employees Retirement System of Ohio raised its holdings in shares of Innophos by 5.9% during the second quarter. Public Employees Retirement System of Ohio now owns 2,824 shares of the specialty chemicals company’s stock worth $124,000 after purchasing an additional 157 shares during the period. Rhumbline Advisers raised its holdings in shares of Innophos by 1.2% during the second quarter. Rhumbline Advisers now owns 39,776 shares of the specialty chemicals company’s stock worth $1,744,000 after purchasing an additional 456 shares during the period. Voya Investment Management LLC raised its holdings in shares of Innophos by 8.2% during the second quarter. Voya Investment Management LLC now owns 10,214 shares of the specialty chemicals company’s stock worth $448,000 after purchasing an additional 776 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in shares of Innophos by 8.1% during the second quarter. Victory Capital Management Inc. now owns 10,711 shares of the specialty chemicals company’s stock worth $470,000 after purchasing an additional 799 shares during the period. 94.46% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Zacks: Innophos Holdings, Inc. (IPHS) Given Average Recommendation of “Buy” by Brokerages” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/08/zacks-innophos-holdings-inc-iphs-given-average-recommendation-of-buy-by-brokerages.html.

Innophos Company Profile

Innophos Holdings, Inc is a producer of nutritional specialty ingredients with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. The Company also provides bioactive mineral and nutritional ingredients. The Company’s segments include Specialty Phosphates US & Canada, Specialty Phosphates Mexico, and Granular Triple Super Phosphate (GTSP) & Other.

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.